Keros Therapeutics, Inc.KROSNASDAQ
LOADING
|||
Operating Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
61.36%
↑ 475% above average
Average (26q)
-16.37%
Historical baseline
Range
High:385.50%
Low:-395.81%
Volatility
-4773.1%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | 61.36% |
| Q2 2025 | -126.19% |
| Q1 2025 | 385.50% |
| Q4 2024 | 9.21% |
| Q3 2024 | -16.29% |
| Q2 2024 | -4.03% |
| Q1 2024 | -4.37% |
| Q4 2023 | -7.34% |
| Q3 2023 | -4.70% |
| Q2 2023 | -6.35% |
| Q1 2023 | -21.62% |
| Q4 2022 | -14.24% |
| Q3 2022 | 8.96% |
| Q2 2022 | -27.36% |
| Q1 2022 | -395.81% |
| Q4 2021 | 75.91% |
| Q3 2021 | -29.96% |
| Q2 2021 | 1.45% |
| Q1 2021 | -18.64% |
| Q4 2020 | -11.24% |
| Q3 2020 | -9.47% |
| Q2 2020 | -3.90% |
| Q1 2020 | -285.04% |
| Q4 2019 | -17.28% |
| Q3 2019 | 12.26% |
| Q2 2019 | 7.24% |
| Q1 2019 | 0.00% |